MARATTO

article · ALEXMED ePosters

THE ASSOCIATION BETWEEN (RS46522) GENETIC POLYMORPHISM IN THE UBIQUITIN-CONJUGATING ENZYME E2Z AND MYOCARDIAL INFARCTION IN A COHORT OF EGYPTIAN PATIENTS.

Abstract

Myocardial infarction is the most serious type of ACS. According to WHO, ACS is is responsible for 8.9 million deaths about 16% of the world total deaths. The most frequent cause of ACS is atherosclerosis which is a consequence of deposition of foam cells that stimulate macrophages, cytokines, monocytes, T-cells and interleukins that promote cellular apoptosis and activation of ubiquitin system that induce plaque instability and subsequent coronary artery obstruction. Ubiquitin protesome system degrades diverse of proteins through the chain of enzymes, one of these enzymes is ubiquitin conjugating enzyme UBE2Z which is supposed to havea role in MI pathogenesis from initiating atherosclerosis through endothelial dysfunction up to plaque instability. The variant rs46522 is located at intronic region of chromosome17 of UBE2Z gene.AIM:The aim of the present work was to study the association between ubiquitin-conjugating enzyme E2Z rs46522 gene polymorphism and myocardial infarction in a cohort of Egyptian patients.PATIENTS AND METHODS:Subjects were divided into 2 groups:50 newly diagnosed patients suffering from AMI admitted to cardiology department at Alexandria main university and 50 age &sex healthy individuals a control group.

Research topics

  • Health, Environment, Cognitive Aging
  • Genetics and Neurodevelopmental Disorders

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/alexpo.2025.373989.2128

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.